Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

The effects of parenteral prostacyclin therapy as add-on treatment to oral compounds in Eisenmenger syndrome

Michele D'Alto, Andrew Constantine, Olga Hajnalka Balint, Emanuele Romeo, Paola Argiento, Laszlo Ablonczy, Nika Skoro-Sajer, George Giannakoulas, Konstantinos Dimopoulos
European Respiratory Journal 2019 54: 1901401; DOI: 10.1183/13993003.01401-2019
Michele D'Alto
1Dept of Cardiology, University “L. Vanvitelli” – Monaldi Hospital, Naples, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michele D'Alto
Andrew Constantine
2Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrew Constantine
Olga Hajnalka Balint
3György Gottsegen Hungarian Institute of Cardiology, Budapest, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emanuele Romeo
1Dept of Cardiology, University “L. Vanvitelli” – Monaldi Hospital, Naples, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paola Argiento
1Dept of Cardiology, University “L. Vanvitelli” – Monaldi Hospital, Naples, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laszlo Ablonczy
3György Gottsegen Hungarian Institute of Cardiology, Budapest, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nika Skoro-Sajer
4Dept of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George Giannakoulas
5Dept of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Konstantinos Dimopoulos
2Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: k.dimopoulos02@gmail.com
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Extract

Pulmonary arterial hypertension (PAH) develops in 5–10% of patients with congenital heart disease (CHD) [1], and PAH associated with congenital heart disease (PAH-CHD) accounts for a significant proportion of PAH cases (34–42%) [2]. Eisenmenger syndrome is at the extreme end of the spectrum of PAH-CHD, with an untreated 10-year mortality rate of 30–40% [3]. Despite decreasing incidence in developed countries [4], Eisenmenger syndrome is likely to remain a common complication of CHD in low- to middle-income countries [5].

Abstract

In this European cohort of Eisenmenger patients, prostanoid therapy, as part of triple combination therapy, was found to be safe and effective in improving exercise capacity, natriuretic peptide levels and haemodynamic parameters over a 2-year period http://bit.ly/2Zl3W1Z

Footnotes

  • Conflict of interest: M. D'Alto reports grants and personal fees from Actelion, Pfizer, GlaxoSmithKline, Dompè and Bayer/MSD, outside the submitted work.

  • Conflict of interest: A. Constantine reports grants from Actelion, outside the submitted work.

  • Conflict of interest: O.H. Balint reports personal fees from Actelion, Lilly, AOP Orphan and Bayer/MSD, outside the submitted work.

  • Conflict of interest: E. Romeo reports grants and personal fees from GlaxoSmithKline, Dompè and MSD, outside the submitted work.

  • Conflict of interest: P. Argiento reports grants and personal fees from GlaxoSmithKline, Dompè and MSD, outside the submitted work.

  • Conflict of interest: L. Ablonczy has nothing to disclose.

  • Conflict of interest: N. Skoro-Sajer reports grants and personal fees from AOPOrphan Pharmaceuticals, Actelion, Bayer, GlaxoSmithKline, Pfizer and United Therapeutics, outside the submitted work.

  • Conflict of interest: G. Giannakoulas reports grants and personal fees from Actelion, United Therapeutics, Pfizer, GlaxoSmithKline, Bayer/MSD and Lilly, outside the submitted work.

  • Conflict of interest: K. Dimopoulos reports grants, personal fees and non-financial support from Actelion, personal fees from Pfizer, GlaxoSmithKline and Bayer/MSD, outside the submitted work.

  • Received July 2, 2019.
  • Accepted July 26, 2019.
  • Copyright ©ERS 2019
https://www.ersjournals.com/user-licence
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 54 Issue 5 Table of Contents
European Respiratory Journal: 54 (5)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The effects of parenteral prostacyclin therapy as add-on treatment to oral compounds in Eisenmenger syndrome
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
The effects of parenteral prostacyclin therapy as add-on treatment to oral compounds in Eisenmenger syndrome
Michele D'Alto, Andrew Constantine, Olga Hajnalka Balint, Emanuele Romeo, Paola Argiento, Laszlo Ablonczy, Nika Skoro-Sajer, George Giannakoulas, Konstantinos Dimopoulos
European Respiratory Journal Nov 2019, 54 (5) 1901401; DOI: 10.1183/13993003.01401-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The effects of parenteral prostacyclin therapy as add-on treatment to oral compounds in Eisenmenger syndrome
Michele D'Alto, Andrew Constantine, Olga Hajnalka Balint, Emanuele Romeo, Paola Argiento, Laszlo Ablonczy, Nika Skoro-Sajer, George Giannakoulas, Konstantinos Dimopoulos
European Respiratory Journal Nov 2019, 54 (5) 1901401; DOI: 10.1183/13993003.01401-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis
  • Ethical obligations for supporting healthcare workers during the COVID-19 pandemic
  • Reversible pulmonary hypertension with multivisceral Whipple's disease
Show more Agora

Research letters

  • Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis
  • Ethical obligations for supporting healthcare workers during the COVID-19 pandemic
  • Reversible pulmonary hypertension with multivisceral Whipple's disease
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society